Ozempic and Fatty Liver Disease — What Australians Need to Know

Fatty liver disease is a condition in which excess fat accumulates in liver cells. The medical name has recently changed: it is now called metabolic dysfunction-associated steatotic liver disease, or MASLD. The older term — non-alcoholic fatty liver disease, or NAFLD — is still widely used by patients and some clinicians, but MASLD is the current preferred terminology in Australian and international guidelines.

MASLD affects approximately 30% of Australian adults. The condition is closely linked to obesity, type 2 diabetes, high blood pressure, and abnormal cholesterol — all of which overlap significantly with the population for whom Ozempic is prescribed.

MASLD exists on a spectrum. At the mild end, fat accumulates in liver cells without causing significant inflammation or scarring. This stage is reversible. As the condition progresses, inflammation develops alongside fat accumulation — a stage called metabolic dysfunction-associated steatohepatitis, or MASH (formerly called non-alcoholic steatohepatitis, or NASH). Left untreated, MASH can progress to liver fibrosis, cirrhosis, and liver failure.

The critical point is this: most people with MASLD have no symptoms until the disease is advanced. Many Australians taking Ozempic for type 2 diabetes or weight management have MASLD without knowing it.

Ozempic (semaglutide 1mg weekly injection) is TGA-approved in Australia for the management of type 2 diabetes. Its higher-dose equivalent, Wegovy (semaglutide 2.4mg weekly), is TGA-approved for chronic weight management and — as of April 2026 — has received provisional TGA approval for treating MASH with moderate to advanced liver fibrosis.

The evidence for semaglutide's effects on the liver is now substantial and comes primarily from the ESSENCE trial — a phase 3 clinical trial published in the New England Journal of Medicine in May 2025, involving 800 participants across 37 countries over 72 weeks.

The results were significant. Among patients taking semaglutide 2.4mg weekly, 62.9% achieved resolution of MASH without worsening of liver fibrosis, compared to 34.3% in the placebo group. Improvements were seen not just in liver fat content but in liver inflammation markers and fibrosis scores — and these improvements were not fully explained by weight loss alone, suggesting semaglutide has direct hepatic effects beyond its metabolic action.

In plain English: semaglutide appears to work on the liver through several pathways simultaneously — reducing fat delivery to liver cells, improving insulin sensitivity, reducing liver inflammation, and directly modifying fibrosis pathways.

The AASLD — the American Association for the Study of Liver Diseases, the leading global body on liver disease — updated its practice guidance in November 2025 to formally include semaglutide as a therapeutic option for MASH with stage F2–F3 fibrosis. In April 2026, Australia's TGA provisionally approved Wegovy for this indication.

This is one of the most commonly searched questions by Australians on Ozempic, and the clinical evidence provides a reassuring answer — with an important nuance.

Ozempic does not typically cause liver damage. In the ESSENCE trial, there were no treatment discontinuations due to liver enzyme elevations, demonstrating that semaglutide has a highly favourable liver safety profile. The FDA prescribing information for semaglutide explicitly states that hepatic impairment does not affect drug exposure, and no dose adjustment is required for patients with any degree of liver impairment.

However, rapid weight loss from Ozempic can temporarily stress the liver. Patients losing weight at a rate greater than 1–1.5kg per week experience rapid mobilisation of fat from body stores. This can temporarily increase the delivery of fatty acids to the liver, elevating liver enzymes — ALT and AST — in the short term. These elevations are generally self-limiting and resolve as weight loss stabilises. They are not a sign of liver damage in the same way that viral hepatitis or alcohol-related liver disease would be.

The nuance: if you had undiagnosed MASLD or elevated liver enzymes before starting Ozempic, and nobody checked your baseline liver function, you may not know whether any change in your liver enzymes is related to the medication, to pre-existing liver disease, or to the metabolic changes happening as you lose weight. This is why baseline testing and monitoring matter.

The Medical Journal of Australia published a consensus statement in September 2025 recommending that all adults with type 2 diabetes, obesity, or two or more metabolic risk factors be assessed for MASLD. The recommended first-line test is a FIB-4 score — a simple calculation using your age, and the results of routine blood tests (ALT, AST, and platelets) that most Australians taking Ozempic will already have.

A FIB-4 score below 1.3 indicates low risk of advanced liver fibrosis — no further action needed, repeat in three years.

A FIB-4 score above 2.67 indicates high risk — direct referral to a hepatologist or gastroenterologist.

A FIB-4 score between 1.3 and 2.67 is the indeterminate range — and this is where the majority of patients land. For this group, the MJA consensus statement recommends second-line assessment with liver elastography (also called a FibroScan or vibration-controlled transient elastography). This is a non-invasive ultrasound-based scan that measures liver stiffness and fat content without the need for a liver biopsy.

If you are taking Ozempic and have not had your FIB-4 score calculated, ask your GP at your next appointment.

Not automatically — but in some circumstances, yes.

You should discuss a liver scan with your GP if:

• You have type 2 diabetes and have not been assessed for MASLD
• You have had elevated liver enzymes (ALT, AST, GGT) on any blood test
• You have obesity (BMI above 30) or central abdominal fat
• Your FIB-4 score comes back in the indeterminate range (1.3–2.67)
• You have a family history of liver disease, cirrhosis, or liver cancer
• You consume alcohol regularly alongside Ozempic

If any of these apply, a liver elastography scan can tell you with a high degree of accuracy whether your liver has significant fibrosis — without a biopsy, without hospital admission, and without any radiation. The scan takes approximately 10–15 minutes and most Australian clinics do not require a GP referral to attend.

Liver elastography measures liver stiffness — a proxy for fibrosis and scarring — by sending a controlled mechanical vibration through the skin of the abdomen and measuring how quickly it travels through liver tissue. Stiffer tissue (more scarring) transmits the vibration faster. The result is reported in kilopascals (kPa).

Most elastography devices also measure liver fat content using a metric called the controlled attenuation parameter (CAP), reported in decibels per metre (dB/m). This gives a picture of both the degree of fat accumulation and any associated scarring in a single 10-minute scan.

A liver stiffness measurement below 8 kPa is generally considered to indicate no significant fibrosis. Values above 12–13 kPa suggest advanced fibrosis and warrant specialist review.

Liver elastography clinics are available in most major Australian cities, including Sydney, Melbourne, Brisbane, Adelaide, Perth, Hobart, and Canberra. A growing number of clinics accept self-referred patients — you do not always need a GP referral to attend, though having one helps the clinic interpret your results in clinical context.

Elastography Australia is the national directory of liver elastography clinics and specialists. You can search for a clinic near you by suburb, state, or city.

Find a liver elastography clinic near you →